{"transactions":[{"id":2953584,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":47690,"kind":"organization","name":"Presidio Management Group XII, L.L.C.","position":1,"cik":"0001734820","reported_name":"Presidio Management Group XII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":49117,"kind":"organization","name":"U.S. Venture Partners XII, L.P.","position":2,"cik":"0001734819","reported_name":"U.S. Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144834,"kind":"organization","name":"U.S. Venture Partners XII-A, L.P.","position":3,"cik":"0001754875","reported_name":"U.S. Venture Partners XII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21218,"kind":"person","name":"Tansey Casey M","position":4,"cik":"0001474322","reported_name":"Tansey Casey M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series C Stock","published_at":"2020-12-09T02:04:04.000Z","date":"2020-12-08","kind":"exercise","acquired":false,"shares":54496,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By U.S. Venture Partners XII-A, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common  Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common  Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common  Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common  Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Presidio Management Group XII, L.L.C. (\"PMG XII\"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the \"USVP XII Funds\"), has sole voting and dispositive power with respect to the shares held by the USVP XII.  Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":14677},"source":{"system":"sec-edgar","filing":"0001548538-20-000027","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1734820/000154853820000027/edgar.xml","form_type":"4"}},{"id":2953583,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":47690,"kind":"organization","name":"Presidio Management Group XII, L.L.C.","position":1,"cik":"0001734820","reported_name":"Presidio Management Group XII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":49117,"kind":"organization","name":"U.S. Venture Partners XII, L.P.","position":2,"cik":"0001734819","reported_name":"U.S. Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144834,"kind":"organization","name":"U.S. Venture Partners XII-A, L.P.","position":3,"cik":"0001754875","reported_name":"U.S. Venture Partners XII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21218,"kind":"person","name":"Tansey Casey M","position":4,"cik":"0001474322","reported_name":"Tansey Casey M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series C Stock","published_at":"2020-12-09T02:04:04.000Z","date":"2020-12-08","kind":"exercise","acquired":false,"shares":1073793,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By U.S. Venture Partners XII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common  Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common  Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common  Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common  Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Presidio Management Group XII, L.L.C. (\"PMG XII\"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the \"USVP XII Funds\"), has sole voting and dispositive power with respect to the shares held by the USVP XII.  Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":289198},"source":{"system":"sec-edgar","filing":"0001548538-20-000027","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1734820/000154853820000027/edgar.xml","form_type":"4"}},{"id":2953582,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":47690,"kind":"organization","name":"Presidio Management Group XII, L.L.C.","position":1,"cik":"0001734820","reported_name":"Presidio Management Group XII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":49117,"kind":"organization","name":"U.S. Venture Partners XII, L.P.","position":2,"cik":"0001734819","reported_name":"U.S. Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144834,"kind":"organization","name":"U.S. Venture Partners XII-A, L.P.","position":3,"cik":"0001754875","reported_name":"U.S. Venture Partners XII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21218,"kind":"person","name":"Tansey Casey M","position":4,"cik":"0001474322","reported_name":"Tansey Casey M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series B Stock","published_at":"2020-12-09T02:04:04.000Z","date":"2020-12-08","kind":"exercise","acquired":false,"shares":335417,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By U.S. Venture Partners XII-A, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common  Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common  Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common  Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common  Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Presidio Management Group XII, L.L.C. (\"PMG XII\"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the \"USVP XII Funds\"), has sole voting and dispositive power with respect to the shares held by the USVP XII.  Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":90335},"source":{"system":"sec-edgar","filing":"0001548538-20-000027","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1734820/000154853820000027/edgar.xml","form_type":"4"}},{"id":2953581,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":47690,"kind":"organization","name":"Presidio Management Group XII, L.L.C.","position":1,"cik":"0001734820","reported_name":"Presidio Management Group XII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":49117,"kind":"organization","name":"U.S. Venture Partners XII, L.P.","position":2,"cik":"0001734819","reported_name":"U.S. Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144834,"kind":"organization","name":"U.S. Venture Partners XII-A, L.P.","position":3,"cik":"0001754875","reported_name":"U.S. Venture Partners XII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21218,"kind":"person","name":"Tansey Casey M","position":4,"cik":"0001474322","reported_name":"Tansey Casey M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series B Stock","published_at":"2020-12-09T02:04:04.000Z","date":"2020-12-08","kind":"exercise","acquired":false,"shares":6609027,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By U.S. Venture Partners XII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common  Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common  Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common  Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common  Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Presidio Management Group XII, L.L.C. (\"PMG XII\"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the \"USVP XII Funds\"), has sole voting and dispositive power with respect to the shares held by the USVP XII.  Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1779969},"source":{"system":"sec-edgar","filing":"0001548538-20-000027","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1734820/000154853820000027/edgar.xml","form_type":"4"}},{"id":2953580,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":47690,"kind":"organization","name":"Presidio Management Group XII, L.L.C.","position":1,"cik":"0001734820","reported_name":"Presidio Management Group XII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":49117,"kind":"organization","name":"U.S. Venture Partners XII, L.P.","position":2,"cik":"0001734819","reported_name":"U.S. Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144834,"kind":"organization","name":"U.S. Venture Partners XII-A, L.P.","position":3,"cik":"0001754875","reported_name":"U.S. Venture Partners XII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21218,"kind":"person","name":"Tansey Casey M","position":4,"cik":"0001474322","reported_name":"Tansey Casey M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-09T02:04:04.000Z","date":"2020-12-08","kind":"purchase","acquired":true,"shares":47619,"price":21,"value":999999.0,"ownership":{"direct":false,"nature":"Directly owned by Tansey"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were purchased in the Issuer's initial public offering."}],"balance_after":47619,"source":{"system":"sec-edgar","filing":"0001548538-20-000027","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1734820/000154853820000027/edgar.xml","form_type":"4"}},{"id":2953579,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":47690,"kind":"organization","name":"Presidio Management Group XII, L.L.C.","position":1,"cik":"0001734820","reported_name":"Presidio Management Group XII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":49117,"kind":"organization","name":"U.S. Venture Partners XII, L.P.","position":2,"cik":"0001734819","reported_name":"U.S. Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144834,"kind":"organization","name":"U.S. Venture Partners XII-A, L.P.","position":3,"cik":"0001754875","reported_name":"U.S. Venture Partners XII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21218,"kind":"person","name":"Tansey Casey M","position":4,"cik":"0001474322","reported_name":"Tansey Casey M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-09T02:04:04.000Z","date":"2020-12-08","kind":"exercise","acquired":true,"shares":14677,"ownership":{"direct":false,"nature":"By U.S. Venture Partners XII-A, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common  Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Presidio Management Group XII, L.L.C. (\"PMG XII\"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the \"USVP XII Funds\"), has sole voting and dispositive power with respect to the shares held by the USVP XII.  Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein."}],"balance_after":105012,"source":{"system":"sec-edgar","filing":"0001548538-20-000027","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1734820/000154853820000027/edgar.xml","form_type":"4"}},{"id":2953578,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":47690,"kind":"organization","name":"Presidio Management Group XII, L.L.C.","position":1,"cik":"0001734820","reported_name":"Presidio Management Group XII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":49117,"kind":"organization","name":"U.S. Venture Partners XII, L.P.","position":2,"cik":"0001734819","reported_name":"U.S. Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144834,"kind":"organization","name":"U.S. Venture Partners XII-A, L.P.","position":3,"cik":"0001754875","reported_name":"U.S. Venture Partners XII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21218,"kind":"person","name":"Tansey Casey M","position":4,"cik":"0001474322","reported_name":"Tansey Casey M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-09T02:04:04.000Z","date":"2020-12-08","kind":"exercise","acquired":true,"shares":90335,"ownership":{"direct":false,"nature":"By U.S. Venture Partners XII-A, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common  Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Presidio Management Group XII, L.L.C. (\"PMG XII\"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the \"USVP XII Funds\"), has sole voting and dispositive power with respect to the shares held by the USVP XII.  Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein."}],"balance_after":90335,"source":{"system":"sec-edgar","filing":"0001548538-20-000027","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1734820/000154853820000027/edgar.xml","form_type":"4"}},{"id":2953577,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":47690,"kind":"organization","name":"Presidio Management Group XII, L.L.C.","position":1,"cik":"0001734820","reported_name":"Presidio Management Group XII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":49117,"kind":"organization","name":"U.S. Venture Partners XII, L.P.","position":2,"cik":"0001734819","reported_name":"U.S. Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144834,"kind":"organization","name":"U.S. Venture Partners XII-A, L.P.","position":3,"cik":"0001754875","reported_name":"U.S. Venture Partners XII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21218,"kind":"person","name":"Tansey Casey M","position":4,"cik":"0001474322","reported_name":"Tansey Casey M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-09T02:04:04.000Z","date":"2020-12-08","kind":"exercise","acquired":true,"shares":289198,"ownership":{"direct":false,"nature":"By U.S. Venture Partners XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common  Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Presidio Management Group XII, L.L.C. (\"PMG XII\"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the \"USVP XII Funds\"), has sole voting and dispositive power with respect to the shares held by the USVP XII.  Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein."}],"balance_after":2069167,"source":{"system":"sec-edgar","filing":"0001548538-20-000027","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1734820/000154853820000027/edgar.xml","form_type":"4"}},{"id":2953576,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":47690,"kind":"organization","name":"Presidio Management Group XII, L.L.C.","position":1,"cik":"0001734820","reported_name":"Presidio Management Group XII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":49117,"kind":"organization","name":"U.S. Venture Partners XII, L.P.","position":2,"cik":"0001734819","reported_name":"U.S. Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144834,"kind":"organization","name":"U.S. Venture Partners XII-A, L.P.","position":3,"cik":"0001754875","reported_name":"U.S. Venture Partners XII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21218,"kind":"person","name":"Tansey Casey M","position":4,"cik":"0001474322","reported_name":"Tansey Casey M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-09T02:04:04.000Z","date":"2020-12-08","kind":"exercise","acquired":true,"shares":1779969,"ownership":{"direct":false,"nature":"By U.S. Venture Partners XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common  Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Presidio Management Group XII, L.L.C. (\"PMG XII\"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the \"USVP XII Funds\"), has sole voting and dispositive power with respect to the shares held by the USVP XII.  Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein."}],"balance_after":1779969,"source":{"system":"sec-edgar","filing":"0001548538-20-000027","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734820/000154853820000027/edgar.xml","form_type":"4"}}]}